Companies such as Bristol-Myers Squibb Company (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), AstraZeneca (U.K.), are the major companies in the nivolumab market.
In April 2025, The U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for adult and pediatric patients aged 12 and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. In March 2025, A report highlighted that the PD-1 inhibitor drugs market, which includes nivolumab, is set for significant growth from 2025 to 2035, driven by advancements in precision medicine and global healthcare investments
The countries covered in the nivolumab market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.